Aptuit LLC announced that the company has reached an agreement on a multiyear extension of its strategic partnership with GlaxoSmithKline (GSK) for dedicated drug development work at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The Verona site – formerly known as GSK’s Medicines Research Centre – was acquired by Aptuit from GSK in 2010.
Timothy C. Tyson, Chairman, Aptuit LLC said, “This multiyear extension of our partnership with GSK reaffirms that our Verona site continues to deliver scientific excellence that is recognized by our customers. Since we finalized our original agreement with GSK in 2010, we have successfully transformed the Verona site from a pharmaceutical research center to a world-class drug discovery and development outsourcing capability.”
Mr. Tyson explained that during the two years since the Verona site became part of Aptuit it has effectively transitioned to a lean, flexible, customer-focused pharmaceutical services operation. To date, the Verona site has had approximately 50 successful audits and has delivered work for more than 90 clients. Mr. Tyson added, “Aptuit initiatives in Verona, such as Lean Six Sigma, are resulting in productivity benefits across our business lines. The high level of quality and regulatory compliance demonstrated in our work has been noticeable to the more than 200 customers who have visited the site since 2010.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.